New Combined Vaccine To Protect Children From Chickenpox

Expanding Childhood Immunisation

Young children in the UK will soon have access to protection against chickenpox through the NHS. Starting in January, a new combined vaccine known as MMRV will be added to the standard childhood vaccination schedule. This updated jab replaces the previous MMR vaccine by providing integrated protection against measles, mumps, rubella, and varicella, which is the medical term for chickenpox.

The introduction of the MMRV vaccine aims to significantly lower the number of chickenpox cases across the population. While the vaccine does not provide a total guarantee of lifetime immunity, health experts indicate that it greatly reduces the likelihood of contracting the virus or suffering from a severe case of the illness. This strategic move aligns the UK with several other nations, including Canada, Australia, Germany, and the US, which already provide routine varicella vaccinations to their pediatric populations.

Understanding The Varicella Virus

Chickenpox is a highly contagious disease caused by the varicella zoster virus. It spreads rapidly through direct person-to-person contact or via airborne droplets released during coughs and sneezes. Because it is so easily transmitted, it is common for children to contract the virus; approximately half of all children have experienced the illness by the time they reach their fourth birthday. However, individuals of any age can be affected if they have not previously had the disease or been vaccinated.

The symptoms typically begin with a general feeling of being unwell, accompanied by muscle aches and a fever. A few days after these initial signs, an itchy, spotty rash develops. These red or pink dots can appear anywhere on the body, including the inside of the mouth. The spots eventually fill with fluid to become blisters before crusting over into scabs. A person remains contagious from two days before the rash first appears until all the spots have formed scabs, a process that usually takes about five days.

Vaccination Schedules And Eligibility

The rollout of the MMRV vaccine follows a specific timeline based on a child’s date of birth. Children born after January 1, 2026, will automatically receive two doses of the vaccine, administered at 12 months and 18 months of age. To ensure broader protection, a catch-up programme has been established for older children.

For those born on or after January 1, 2025, two doses will be offered at 12 and 18 months. Children born between July 1, 2024, and December 31, 2024, will receive two doses, with the first at 18 months and the second at 3 years and 4 months. Those born between September 1, 2022, and June 30, 2024, are eligible for a single dose at 3 years and 4 months. Finally, children born between January 1, 2020, and August 31, 2022, will be offered a single dose later in 2026. GP surgeries are responsible for contacting families to schedule these appointments.

Safety And Medical Considerations

The MMRV vaccine is a live vaccine, meaning it contains a weakened version of the varicella zoster virus. Because of this composition, it is not recommended for individuals with compromised immune systems, such as those undergoing chemotherapy or living with HIV. While severe allergic reactions are very rare, the vaccine is considered a safe way to prevent serious complications associated with the virus.

Historically, there were concerns that widespread childhood vaccination against chickenpox might lead to an increase in shingles, a related condition. However, a recent long-term study from the US has disproved this theory, paving the way for the current recommendation. The decision to implement the MMRV vaccine follows a November 2023 recommendation from the JCVI, the committee that advises the government on vaccinations. This comes at a time when uptake for main childhood vaccines in England has fallen below the 95% target, with only 91.9% of five-year-olds receiving one dose of the MMR vaccine.